Edap Tms (NASDAQ:EDAP) Lifted to Hold at Zacks Investment Research

Edap Tms (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

EDAP has been the topic of a number of other research reports. ValuEngine raised shares of YY from a “sell” rating to a “hold” rating in a research note on Friday, June 7th. TheStreet downgraded shares of Timkensteel from a “c-” rating to a “d+” rating in a research note on Monday, June 17th. Finally, HC Wainwright set a $4.00 target price on shares of Uranium Energy and gave the company a “buy” rating in a research note on Tuesday, June 11th.

EDAP stock remained flat at $$2.68 during midday trading on Tuesday. 17,500 shares of the company’s stock were exchanged, compared to its average volume of 170,190. Edap Tms has a twelve month low of $1.35 and a twelve month high of $5.42. The company has a market capitalization of $77.72 million, a P/E ratio of 134.00 and a beta of 1.94. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.40. The stock has a 50-day moving average of $2.76.

Edap Tms (NASDAQ:EDAP) last issued its earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.01. Edap Tms had a negative net margin of 0.36% and a negative return on equity of 1.13%. The firm had revenue of $11.50 million during the quarter, compared to analyst estimates of $13.25 million. Equities analysts forecast that Edap Tms will post 0.08 EPS for the current year.

A hedge fund recently raised its stake in Edap Tms stock. Fosun International Ltd increased its stake in Edap Tms SA (NASDAQ:EDAP) by 45.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 363,485 shares of the medical equipment provider’s stock after purchasing an additional 114,342 shares during the period. Fosun International Ltd owned 1.25% of Edap Tms worth $1,072,000 as of its most recent filing with the Securities & Exchange Commission.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.